Significant alterations in the levels of ficolin-2, antigenic MBL, MASPs, and MAp44 levels, along with anti-ficolin autoantibodies, and their associations with clinical manifestations, disease activity and complement-related parameters suggested their potential utility as biomarkers in SLE. Here, MBL2 is linked to systemic lupus erythematosus.